The Chairman of one of the busiest Contract Development and Manufacturing Organizations (CDMOs), Charles River Laboratories, has warned that biopharma companies will likely cut drug discovery activity in the coming months due to a lack of demand recovery and softening trends. This will result in a negative impact on the growth prospects for the second half of the year. Other global biopharma companies are likely to restructure, cut budgets, and prune pipelines due to the Inflation Reduction Act, patent expirations, or both.
Google strengthens secure enterprise access from BYOD Android devices
Google has launched Device Trust from Android Enterprise, a tool designed to boost security for private Android devices used for work. Device Trust uses over
